Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study

被引：15

作者：

Patti, Francesco ^{[1
]}

Chisari, Clara Grazia ^{[1
]}

Solaro, Claudio ^{[2
,3
]}

Benedetti, Maria Donata ^{[4
]}

Berra, Eliana ^{[5
]}

Bianco, Assunta ^{[6
]}

Bossio, Roberto Bruno ^{[7
,8
]}

Buttari, Fabio ^{[9
]}

Castelli, Letizia ^{[10
]}

Cavalla, Paola ^{[11
]}

Cerqua, Raffaella ^{[12
]}

Costantino, Gianfranco ^{[13
]}

Gasperini, Claudio ^{[14
]}

Guareschi, Angelica ^{[15
]}

Ippolito, Domenico ^{[16
]}

Lanzillo, Roberta ^{[17
]}

Maniscalco, Giorgia Teresa ^{[18
]}

Matta, Manuela ^{[19
,20
]}

Paolicelli, Damiano ^{[21
]}

Petrucci, Loredana ^{[22
]}

Pontecorvo, Simona ^{[23
]}

Righini, Isabella ^{[24
]}

Russo, Margherita ^{[25
]}

Sacca, Francesco ^{[17
]}

Salamone, Giovanna ^{[26
]}

Signoriello, Elisabetta ^{[27
]}

Spinicci, Gabriella ^{[28
]}

Spitaleri, Daniele ^{[29
]}

Tavazzi, Eleonora ^{[30
]}

Trotta, Maria ^{[31
]}

Zaffaroni, Mauro ^{[32
]}

Zappia, Mario ^{[1
]}

机构：

[1] Univ Catania, Dept GF Ingrassia, Sect Neurosci, Catania, Italy

[2] ML Novarese Hosp Moncrivello, Dept Neurol, ASL3 Genovese, Genoa, Italy

[3] ML Novarese Hosp Moncrivello, Dept Rehabil, Genoa, Italy

[4] Univ Verona, Dept Neurosci Biomed & Movement Sci, Sect Neurol, Verona, Italy

[5] Neurol Inst C Mondino, Neurorehabil Unit, Dept Neurol, Pavia, Italy

[6] Fdn Policlin Univ A Gemelli IRCCS, Multiple Sclerosis Unit, Rome, Italy

[7] Prov Hlth Author Cosenza, Neurol Operating Unit, Cosenza, Italy

[8] Prov Hlth Author Cosenza, Multiple Sclerosis Ctr, Cosenza, Italy

[9] Tor Vergata Univ, Dept Syst Med, Synapt Immunopathol Lab, Rome, Italy

[10] IRCCS Fdn Don Carlo Gnocchi, Neurol Unit, Milan, Italy

[11] Hlth & Sci City Univ Hosp Turin, Multiple Sclerosis Ctr, Dept Neurosci & Mental Hlth, Turin, Italy

[12] Marche Polytech Univ, Dept Expt & Clin Med, Neurol Clin, Ancona, Italy

[13] Foggia Hosp, Demyelinating Dis Ctr, Foggia, Italy

[14] San Camillo Forlanini Hosp, Multiple Sclerosis Ctr, Rome, Italy

[15] Fidenza Hosp, Multiple Sclerosis Ctr, Med Dept, Fidenza, PR, Italy

[16] Univ Campania Luigi Vanvitelli, Dept Adv Med & Surg Sci, Naples, Italy

[17] Univ Federico II, Dept Neurosci Reprod & Odontostomatol Sci, Naples, Italy

[18] Osped Cardarelli, Dept Neurol, Naples, Italy

[19] San Luigi Gonzaga Univ Hosp, CReSM Reg Referring Ctr Multiple Sclerosis, Neurobiol Unit, Neurol 2, Orbassano, TO, Italy

[20] NICO, Orbassano, TO, Italy

[21] Univ Bari Aldo Moro, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy

[22] Univ Hosp Pisa, Multiple Sclerosis Ctr, Pisa, Italy

[23] Univ Rome, Multiple Sclerosis Ctr, Dept Neurol & Psychiat Sapienza, Rome, Italy

[24] Univ Florence, Dept NEUROFARBA, Florence, Italy

[25] IRCCS Bonino Pulejo Ctr, Multiple Sclerosis Ctr, Messina, Italy

[26] Villa Sofia Cervello Hosp, Neuroimmunol Unit, Palermo, Italy

[27] Univ Campania Luigi Vanvitelli, Multiple Sclerosis Ctr, Dept Clin & Expt Med, Div Neurol 2, Naples, Italy

[28] Univ Cagliari, Multiple Sclerosis Ctr, Dept Med Sci & Publ Hlth, Cagliari, Italy

[29] Azienda Osped Rilievo Nazl San Giuseppe Moscati, Avellino, Italy

[30] Fdn Don C Gnocchi, Multiple Sclerosis Ctr, Unit Motor Neurorehabil, IRCCS Santa Maria Nascente, Milan, Italy

[31] Magna Graecia Univ Catanzaro, Inst Neurol, Catanzaro, Italy

[32] Gallarate Hosp, Multiple Sclerosis Ctr, ASST Valle Olona, Gallarate, VA, Italy

来源：

NEUROLOGICAL SCIENCES | 2020年 / 41卷 / 10期

关键词：

Multiple sclerosis; Clinical practice; Spasticity-related symptoms; THC; CBD; QUALITY-OF-LIFE; DOUBLE-BLIND; NEUROPATHIC PAIN; SATIVEX(R); NABIXIMOLS; CANNABINOIDS; MANAGEMENT; BLADDER; PATIENT; TRIAL;

D O I：

10.1007/s10072-020-04413-6

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Introduction The approval of 9-delta-tetrahydocannabinol (THC)+cannabidiol (CBD) oromucosal spray (Sativex (R)) in Italy as an add-on medication for the management of moderate to severe spasticity in multiple sclerosis (MS) has provided a new opportunity for MS patients with drug-resistant spasticity. We aimed to investigate the improvement of MS spasticity-related symptoms in a large cohort of patients with moderate to severe spasticity in daily clinical practice. Materials and methods MS patients with drug-resistant spasticity were recruited from 30 Italian MS centers. All patients were eligible for THC:CBD treatment according to the approved label: >= 18 years of age, at least moderate spasticity (MS spasticity numerical rating scale [NRS] score >= 4) and not responding to the common antispastic drugs. Patients were evaluated at baseline (T0) and after 4 weeks of treatment (T1) with the spasticity NRS scale and were also asked about meaningful improvements in 6 key spasticity-related symptoms. Results Out of 1615 enrolled patients, 1432 reached the end of the first month trial period (T1). Of these, 1010 patients (70.5%) reached a >= 20% NRS score reduction compared with baseline (initial responders; IR). We found that 627 (43.8% of 1432) patients showed an improvement in at least one spasticity-related symptom (SRSr group), 543 (86.6%) of them belonging to the IR group and 84 (13.4%) to the spasticity NRS non-responders group. Conclusion Our study confirmed that the therapeutic benefit of cannabinoids may extend beyond spasticity, improving spasticity-related symptoms even in non-NRS responder patients.

引用

页码：2905 / 2913

页数：9

共 37 条

[1] Arroyo R, 2014, J COMP EFFECT RES, V3, P435, DOI [10.2217/CER.14.30, 10.2217/cer.14.30]
[2] Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study
Arroyo, Rafael
Massana, Mariona
Vila, Carlos
[J]. INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2013, 123 (12) : 850 - 858
[3] Interactions between Δ-9THC and capsaicin on isolated lamb bladder detrusor
Bartocci, C
Evandri, MG
Tucci, P
Bolle, P
[J]. FARMACO, 2001, 56 (5-7): : 349 - 351
[4] Epidemiology and clinical assessment of spasticity in multiple sclerosis
Bensmail, D.
Vermersch, P.
[J]. REVUE NEUROLOGIQUE, 2012, 168 : S45 - S50
[5] Advances in the Management of Multiple Sclerosis Spasticity: Multiple Sclerosis Spasticity Nervous Pathways
Centonze, Diego
[J]. EUROPEAN NEUROLOGY, 2014, 72 : 6 - 8
[6] Walking improvements with nabiximols in patients with multiple sclerosis
Coghe, G.
Pau, M.
Corona, F.
Frau, J.
Lorefice, L.
Fenu, G.
Spinicci, G.
Mamusa, E.
Musu, L.
Massole, S.
Massa, R.
Marrosu, M. G.
Cocco, E.
[J]. JOURNAL OF NEUROLOGY, 2015, 262 (11) : 2472 - 2477
[7] Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence
Colizzi, Marco
McGuire, Philip
Pertwee, Roger G.
Bhattacharyya, Sagnik
[J]. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2016, 64 : 359 - 381
[8] A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
Collin, C.
Ehler, E.
Waberzinek, G.
Alsindi, Z.
Davies, P.
Powell, K.
Notcutt, W.
O'Leary, C.
Ratcliffe, S.
Novakova, I.
Zapletalova, O.
Pikova, J.
Ambler, Z.
[J]. NEUROLOGICAL RESEARCH, 2010, 32 (05) : 451 - 459
[9] Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation
Costa, B
Giagnoni, G
Franke, C
Trovato, AE
Colleoni, M
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2004, 143 (02) : 247 - 250
[10] Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: A post hoc analysis of a randomized, double-blind, placebo-controlled trial
Farrar, John T.
Troxel, Andrea B.
Stott, Colin
Duncombe, Paul
Jensen, Mark P.
[J]. CLINICAL THERAPEUTICS, 2008, 30 (05) : 974 - 985

← 1 2 3 4 →